Similarly, other studies have shown that simultaneous targeting of Id1 and Id3, compared to targeting of each gene alone, is more effective at inhibiting tumor growth and metastatic potential of breast, colorectal, gastric, and pancreatic cancers [37]–[40]. The gene discussed is ID3; the disease is neoplasm.